Haemonetics ( (HAE) ) just unveiled an update.
Haemonetics Corporation announced executive leadership updates on March 3, 2025, appointing Frank W. Chan, Ph.D. as Executive Vice President, Chief Operating Officer, effective April 7, 2025, and promoting Roy Galvin to Executive Vice President, Chief Commercial Officer. Chan, with over 25 years of experience in medical device and healthcare technology, will oversee research, development, and global manufacturing, while Galvin will expand his role to include the Global Hospital business. These appointments aim to strengthen Haemonetics’ leadership and support its long-term growth strategy.
More about Haemonetics
Haemonetics Corporation is a global healthcare company that provides innovative medical products and solutions aimed at improving patient care and reducing healthcare costs. The company focuses on important medical markets, including blood and plasma component collection, surgical suites, and hospital transfusion services.
YTD Price Performance: -16.45%
Average Trading Volume: 856,495
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.29B
See more data about HAE stock on TipRanks’ Stock Analysis page.